1819 related articles for article (PubMed ID: 30696576)
1. Osteoporosis.
Compston JE; McClung MR; Leslie WD
Lancet; 2019 Jan; 393(10169):364-376. PubMed ID: 30696576
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Leder BZ
Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
[TBL] [Abstract][Full Text] [Related]
4. Using Osteoporosis Therapies in Combination.
McClung MR
Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
[TBL] [Abstract][Full Text] [Related]
5. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
[TBL] [Abstract][Full Text] [Related]
7. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
8. Current Status of Bone-Forming Therapies for the Management of Osteoporosis.
Sølling ASK; Harsløf T; Langdahl B
Drugs Aging; 2019 Jul; 36(7):625-638. PubMed ID: 31066015
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
[TBL] [Abstract][Full Text] [Related]
10. New Frontiers in Osteoporosis Therapy.
Cheng C; Wentworth K; Shoback DM
Annu Rev Med; 2020 Jan; 71():277-288. PubMed ID: 31509477
[TBL] [Abstract][Full Text] [Related]
11. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
12. Abaloparatide and the Spine: A Narrative Review.
Thompson JC; Wanderman N; Anderson PA; Freedman BA
Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
[TBL] [Abstract][Full Text] [Related]
13. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
Kamata Y; Minota S
Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
[TBL] [Abstract][Full Text] [Related]
14. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
15. Update on osteoporosis treatment.
Nogués X; Martinez-Laguna D
Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
[TBL] [Abstract][Full Text] [Related]
16. Advances in treatment of glucocorticoid-induced osteoporosis.
Hsu E; Nanes M
Curr Opin Endocrinol Diabetes Obes; 2017 Dec; 24(6):411-417. PubMed ID: 28857847
[TBL] [Abstract][Full Text] [Related]
17. Use of teriparatide in osteoporotic fracture patients.
Collinge C; Favela J
Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
[TBL] [Abstract][Full Text] [Related]
18. An overview of the management of osteoporosis in the aging female population.
Amin U; McPartland A; O'Sullivan M; Silke C
Womens Health (Lond); 2023; 19():17455057231176655. PubMed ID: 37218715
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.
Meier C; Uebelhart B; Aubry-Rozier B; Birkhäuser M; Bischoff-Ferrari HA; Frey D; Kressig RW; Lamy O; Lippuner K; Stute P; Suhm N; Ferrari S
Swiss Med Wkly; 2017; 147():w14484. PubMed ID: 28871570
[TBL] [Abstract][Full Text] [Related]
20. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
